drugset / Trial / NCT07210125

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125

Phase 4 Active not recruiting 75 enrolled Kelley-Ross & Associates, Inc. Gilead Sciences · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.

Timeline

Start
2025-09-16
Primary completion
2027-03-31
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenacapavir Small molecule Oral